Innate Pharma
Clinical-stage biotech developing immunotherapies for cancer using the innate immune system.
IPH | PA
Overview
Corporate Details
- ISIN(s):
- FR0010331421 (+1 more)
- LEI:
- 9695002Y8420ZB8HJE29
- Country:
- France
- Address:
- 117 AVENUE DE LUMINY, 13009 MARSEILLE
- Website:
- http://www.innate-pharma.com/
- Sector:
- Manufacturing
Description
Innate Pharma is a clinical-stage, oncology-focused biotechnology company that develops immunotherapies for cancer patients. The company's scientific approach is centered on leveraging the innate immune system, particularly Natural Killer (NK) cells, to create novel treatments. Its innovative pipeline is composed of antibody-based therapeutics, including first-in-class monoclonal antibodies, antibody-drug conjugates (ADCs), and multi-specific NK cell engagers based on its proprietary ANKET® platform. Key clinical programs include lacutamab (anti-KIR3DL2), monalizumab (anti-NKG2A) in partnership with AstraZeneca, and a portfolio of NK cell engagers targeting various hematological malignancies and solid tumors.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2021-02-17 07:00 |
Innate Pharma participera à la 10ème conférence annuelle SVB Leerink Global Hea…
|
French | 145.5 KB | ||
| 2021-02-09 07:00 |
Innate Pharma advances lacutamab clinical development program
|
English | 419.6 KB | ||
| 2021-02-03 07:00 |
Innate Pharma organise une conférence avec des experts sur le rôle potentiel de…
|
French | 191.2 KB | ||
| 2021-02-03 07:00 |
Innate Pharma to host key opinion leader discussion on the potential role of la…
|
English | 361.2 KB | ||
| 2021-01-05 07:00 |
Un premier anticorps multispécifique engageant les cellules NK d'Innate sélecti…
|
French | 246.5 KB | ||
| 2021-01-05 07:00 |
Innate's first NK cell engager selected by Sanofi as drug candidate for develop…
|
English | 423.0 KB | ||
| 2021-01-04 07:00 |
Prochains rendez-vous investisseurs d'Innate Pharma
|
French | 145.9 KB | ||
| 2021-01-04 07:00 |
Innate Pharma to participate in upcoming investor conferences
|
English | 315.3 KB | ||
| 2020-12-11 07:00 |
Innate Pharma retourne les droits de commercialisation de Lumoxiti aux Etats-Un…
|
French | 242.0 KB | ||
| 2020-12-03 14:30 |
Innate Pharma présentera des données additionnelles d'efficacité pour monalizum…
|
French | 216.5 KB | ||
| 2020-12-03 14:30 |
Innate Pharma to present additional efficacy data for monalizumab in combinatio…
|
English | 383.2 KB | ||
| 2020-12-02 07:00 |
Innate Pharma publie son calendrier financier pour 2021
|
French | 132.1 KB | ||
| 2020-12-02 07:00 |
Innate Pharma 2021 financial calendar
|
English | 127.0 KB | ||
| 2020-11-17 11:06 |
Half-year financial report - June 30, 2020
|
English | 1.5 MB | ||
| 2020-11-17 11:06 |
Rapport financier semestriel au 30 juin 2020
|
French | 1.5 MB |
Automate Your Workflow. Get a real-time feed of all Innate Pharma filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Innate Pharma
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Innate Pharma via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-01-10 | N/A | Other | Buy | 6,000 | N/A |
| 2024-01-02 | N/A | Other | Buy | 20,000 | N/A |
Peer Companies
